News Releases

Date	Title and Summary	View
Aug 26, 2021	Johnson & Johnson to Participate in the Cantor Virtual Global Healthcare Conference
Aug 25, 2021	Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
Aug 24, 2021	FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
Aug 19, 2021	Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Aug 12, 2021	Johnson & Johnson to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Aug 11, 2021	ETHICON’S ECHELON CIRCULAR POWERED STAPLER ASSOCIATED WITH MAJOR REDUCTION IN SERIOUS COMPLICATIONS FOLLOWING COLORECTAL SURGERY
Aug 09, 2021	Johnson & Johnson to Participate in Barclays Global Consumer Staples Virtual Conference
Jul 30, 2021	UPTRAVI® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
Jul 27, 2021	Johnson & Johnson to Participate in the Virtual Wells Fargo Healthcare Conference
Jul 21, 2021	Johnson & Johnson Reports Q2 2021 Results - Strong sales growth of 27.1% to $23.3 Billion in Second Quarter 2021 with operational growth of 23.0%* and adjusted operational growth of 23.8%* - EPS of $2.35 increased 72.8% in Second Quarter 2021 and adjusted EPS of $2.48 increased 48.5%* - Company increasing 2021 Full-Year guidance for sales